TABLE 1

Response Evaluation of Breast Cancer Therapy by 18F-FDG PET

ReferencenTherapyResult
Mid-therapy
 Wahl et al. (21)11ACR: −48% SUV, NR: −19% SUV
 Bassa et al. (29)15FACAll: −51%SUV
 Schelling et al. (25)24EC or ETmCR: −46% SUV, not mCR: −8% SUV
 Smith et al. (26)30CVAPmCR: −86% SUV, not mCR: −40% SUV
 Mankoff et al. (94)35FAC or AC (weekly)mCR: −65% MRFDG, PR: −49%, MRFDG, NR: −40% MRFDG
 Rousseau et al. (27)64FEC, EC, ordocetaxelCR or near CR: −96% SUVmax, R: −61% SUVmax, NR: −36% SUVmax
 McDermott et al. (150)96Anthracycline-basedCR or near CR: −41% SUV, other: −27% SUV
 Dunnwald et al. (41)53FAC or AC (weekly)pCR: −82% MRFDG, not pCR: −62% MRFDG
Early therapy
 Wahl et al. (21)11ACR: −22%SUV, NR: no change
 Schelling et al. (25)24EC or ETmCR: −54% SUV, not mCR: −19% SUV
 Smith et al. (26)30CVAPmCR: −77% SUV, not mCR: +1% SUV
 Rousseau et al. (27)64FEC, EC, ordocetaxelCR or near CR: −60% SUVmax, R: −36% SUVmax, NR: −16% SUVmax
 McDermott et al. (150)96Anthracycline-basedCR or near CR: −20% SUV, other: −13% SUV
 Berriolo-Riedinger (28)47FEC, CEX, ET, DCT in HER2+pCR: −85% SUVmax, not pCR: −26% SUVmax
  • AC = doxorubicin/cyclophosphamide; R = responder; NR = nonresponder; FAC = 5-fluorouracil/doxorubicin/cyclophosphamide; EC = epirubicin/cyclophosphamide; ET = epirubicin/paclitaxel; mCR = pathologic macroscopic complete; CVAP = cyclophosphamide/vincristine/doxorubicin/prednisone; MRFDG = FDG metabolic rate; PR = partial responder; NR = nonresponder; pCR = pathologic complete responder; FEC = 5-fluorouracil/epirubicin/cyclophosphamide; CEX = cyclophosphamide/epirubicin/capecitabine; DCT = doxetaxel/carboplatin/trastuzumab.